R. Gosens (Groningen, Netherlands), O. Burghuber (Wien, Austria)
Late Breaking Abstract - Randomised trial of ambulatory management of primary spontaneous pneumothorax
R. Hallifax (Oxfrod, United Kingdom), E. Mckeown (Reading(Oxfordshire), United Kingdom), P. Sivakumar (London, United Kingdom), I. Fairburn (Dunfermline, United Kingdom), C. Peter (Bath, United Kingdom), A. Leitch (Edinburgh, United Kingdom), M. Knight (watford, United Kingdom), A. Stanton (Swindon, United Kingdom), A. Ijaz (Lancaster, United Kingdom), S. Marciniak (Cambridge, United Kingdom), J. Cameron (Bristol, United Kingdom), A. Bhatta (Blackpool, United Kingdom), K. Blyth (Blackpool, United Kingdom), R. Reddy (Kettering, United Kingdom), M. Harris (Edinburgh, United Kingdom), N. Maddekar (Stoke-on-Trent, United Kingdom), S. Walker (Bristol, United Kingdom), A. West (London, United Kingdom), M. Laskawiec-Szkonter (Oxford, United Kingdom), J. Corcoran (Plymouth, United Kingdom), S. Gerry (Oxford, United Kingdom), C. Roberts (Oxford, United Kingdom), J. Harvey (Bristol, United Kingdom), N. Maskell (Bristol, United Kingdom), R. Miller (London, United Kingdom), N. Rahman (Oxford, United Kingdom)
|     |
Late Breaking Abstract - Two Phase 3 Randomized Clinical Trials of Gefapixant, a P2X3 Receptor Antagonist, in Refractory or Unexplained Chronic Cough (COUGH-1 and COUGH-2)
L. McGarvey (Belfast, United Kingdom), S. Birring (London, United Kingdom), A. Morice (Cottingham, United Kingdom), P. Dicpinigaitis (New York, United States of America), I. Pavord (Oxford, United Kingdom), J. Schelfhout (Kenilworth, United States of America), A. Martin Nguyen (Kenilworth, United States of America), Q. Li (Kenilworth, United States of America), A. Tzontcheva (Kenilworth, United States of America), B. Iskold (Kenilworth, United States of America), S. Green (Kenilworth, United States of America), C. La Rosa (Kenilworth, United States of America), D. Muccino (Kenilworth, United States of America), J. Smith (Manchester, United Kingdom)
| |
Wrap-up by discussant and discussion
D. Stolz (Basel, Switzerland)
| |
Late Breaking Abstract - Switching from PDE5i to riociguat in patients with PAH: The REPLACE study
M. Hoeper (Hannover, Germany), H. Ghofrani (Giessen, Germany), H. Al-Hiti (Prague, Czech Republic), R. Benza (Columbus, OH, United States of America), S. Chang (Seoul, Republic of Korea), P. Corris (Newcastle upon Tyne, United Kingdom), S. Gibbs (London, United Kingdom), E. Grünig (Heidelberg, Germany), P. Jansa (Prague, Czech Republic), J. Klinger (Providence, RI, United States of America), D. Langleben (Montreal, QC, Canada), V. Mclaughlin (Ann Arbor, MI, United States of America), G. Meyer (Porto Alegre, Brazil), J. Ota-Arakaki (São Paulo, Brazil), A. Peacock (Glasgow, United Kingdom), T. Pulido (Mexico City, Mexico), S. Rosenkranz (Cologne, Germany), D. Vizza (Rome, Italy), A. Vonk-Noordegraaf (Amsterdam, Netherlands), J. White (Rochester, NY, United States of America), M. Chang (Berlin, Germany), F. Kleinjung (Berlin, Germany), C. Meier (Berlin, Germany), K. Paraschin (São Paulo, Brazil), G. Simonneau (Le Kremlin-Bicêtre, France)
| |
Inhaled Molgramostim Therapy in Autoimmune Pulmonary Alveolar Proteinosis (APAP)
B. Trapnell (Cincinnati, United States of America), Y. Inoue (Osaka, Japan), F. Bonella (Essen, Germany), C. Morgan (London, United Kingdom), S. Jouneau (Rennes, France), E. Bendstrup (Aarhus, Denmark), I. Campo (Pavia, Italy), S. Papiris (Athens, Greece), E. Yamaguchi (Aichi, Japan), E. Cetinkaya (Istanbul, Turkey), M. Ilkovich (St. Petersburg, Russian Federation), M. Kramer (Petah Tikva, Israel), M. Veltkamp (Nieuwegein, Netherlands), M. Kreuter (Heidelberg, Germany), T. Baba (Yokohama, Japan), C. Ganslandt (Austin, United States of America), I. Tarnow (Austin, United States of America), G. Waterer (Perth, Australia), T. Jouhikainen (Austin, United States of America)
| |
Wrap-up by discussant and discussion
M. Humbert (Le Kremlin-Bicêtre, France)
| |